Churchill Capital Corp XI (CCXI)
| Market Cap | 778.13M |
| Revenue (ttm) | n/a |
| Net Income | 655,025 |
| EPS | n/a |
| Shares Out | 55.70M |
| PE Ratio | 1,187.94 |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 1,729,219 |
| Open | 14.37 |
| Previous Close | 14.41 |
| Day's Range | 13.66 - 14.49 |
| 52-Week Range | 10.07 - 19.69 |
| Beta | n/a |
| Analysts | n/a |
| Price Target | n/a |
| Earnings Date | n/a |
About CCXI
Churchill Capital Corp XI does not have significant operations. It intends to effect a merger, amalgamation, share exchange, asset acquisition, share purchase, reorganization, or similar business combination with one or more businesses. The company was incorporated in 2025 and is based in New York, New York.
News
Agility Robotics, Churchill Capital Corp XI submit draft registration statement
Agility Robotics and Churchill Capital Corp XI (CCXI), a special purpose acquisition company, announced the confidential submission of a draft registration statement on Form S-4 with the U.S. SEC. The...
Churchill Capital Corp XI and Agility announce business combination agreement
Agility Robotics,a leading humanoid robotics and physical AI company, and Churchill Capital Corp XI (CCXI) announced they have entered into a definitive business combination agreement. Upon closing of...
Churchill Capital Corp XI Announces the Pricing of Upsized $360 Million Initial Public Offering
Churchill Capital Corp XI announced the pricing of its upsized initial public offering of 36,000,000 units at $10.00 per unit....
Michael Klein's SPAC Churchill Capital XI files for a $300 million IPO
Churchill Capital XI, a blank check company founded by dealmaker and former Citi executive Michael Klein, filed on Tuesday with the SEC to raise up to $300 million in an initial public offering.
Churchill Capital Corp XI IPO Registration Document (S-1)
Churchill Capital Corp XI has filed to go public with an IPO on the NASDAQ.
Can ChemoCentryx Control Challenging Capital Complications?
ChemoCentryx Inc. (CCXI) is facing severe headwinds from current market volatility. Shares are down more than 40% this year and are likely to continue this trend for the coming weeks.
ChemoCentryx: Can Pharma Company Hit Big?
I am neutral on ChemoCentryx (CCXI) as Wall Street analysts are overwhelmingly bullish on it and the average price target indicates strong upside potential over the next year, but the…
ChemoCentryx Stock Is a Highly Speculative Bet
ChemoCentryx (CCXI) is a leading biopharmaceutical firm that works to discover, develop, and market orally-administered therapeutic drugs to combat many autoimmune disorders, inflammatory diseases, an...
ChemoCentryx Q3 Results Surpass Expectations; Street Says Buy
ChemoCentryx, Inc. (CCXI), a biopharmaceutical company specializing in developing new medications for inflammatory and autoimmune diseases and cancer, has reported stronger-than-expected results for t...
ChemoCentryx Stock: Worth Keeping an Eye on
I am neutral on ChemoCentryx (CCXI) because the upside potential embedded in its development pipeline is offset by the speculative nature of the business, and its lack of profitability at…
ChemoCentryx Receives FDA Approval for TAVNEOS; Shares Skyrocket
Shares of biopharmaceutical company ChemoCentryx, Inc., (CCXI) jumped 96% on Friday to close at $38.41 after the company announced that its orally administered selective complement 5a receptor inhibit...
Chemocentryx: A Risky Yet Potentially Lucrative Bet
With shares sitting 73% into the red in 2021, it’s safe to say, Chemocentryx (CCXI) investors have endured a difficult year so far. The alarming decline has mostly been due…
Is Chemocentryx Stock a Buy Right Now? This Is What You Need to Know
Investing in biotechs is a risky business, something those backing Chemocentryx’ (CCXI) success know all too well following last week’s shenanigans. The stock started the week trading at $48.49 per…